Literature DB >> 11669607

Role of LMP1 in immune control of EBV infection.

S Pai1, R Khanna.   

Abstract

The Epstein-Barr virus (EBV) encoded latent membrane protein (LMP1) plays a crucial role in the long-term persistence of this virus within the cells of the immune system. Not only is this protein critical for the transformation of resting B cells by EBV, it also displays pleiotropic effects on various cellular proteins expressed in the host cell. These include up-regulation of expression of B cell activation antigens, adhesion molecules and various components of the antigen processing pathway. Here we discuss how LMP1 acts like an expression 'switch' which, depending on the stage of EBV infection, manoeuvres various pathways that either modulate the immune system towards or against its survival. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669607     DOI: 10.1006/scbi.2001.0412

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  13 in total

1.  Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo.

Authors:  Dimitris Panagopoulos; Panayiotis Victoratos; Maria Alexiou; George Kollias; George Mosialos
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  TRAF6 is a critical regulator of LMP1 functions in vivo.

Authors:  Kelly M Arcipowski; Laura L Stunz; Gail A Bishop
Journal:  Int Immunol       Date:  2013-10-29       Impact factor: 4.823

3.  Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1).

Authors:  Kelly M Arcipowski; Laura L Stunz; John P Graham; Zachary J Kraus; Tony J Vanden Bush; Gail A Bishop
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

4.  Potential selection of LMP1 variants in nasopharyngeal carcinoma.

Authors:  Rachel H Edwards; Diane Sitki-Green; Dominic T Moore; Nancy Raab-Traub
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.

Authors:  Shu-Chen Liu; Ngan-Ming Tsang; Wen-Che Chiang; Kai-Ping Chang; Chuen Hsueh; Ying Liang; Jyh-Lyh Juang; Kai-Ping N Chow; Yu-Sun Chang
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

Review 6.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

7.  EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.

Authors:  Wenfeng Fang; Jianwei Zhang; Shaodong Hong; Jianhua Zhan; Nan Chen; Tao Qin; Yanna Tang; Yaxiong Zhang; Shiyang Kang; Ting Zhou; Xuan Wu; Wenhua Liang; Zhihuang Hu; Yuxiang Ma; Yuanyuan Zhao; Ying Tian; Yunpeng Yang; Cong Xue; Yue Yan; Xue Hou; Peiyu Huang; Yan Huang; Hongyun Zhao; Li Zhang
Journal:  Oncotarget       Date:  2014-12-15

Review 8.  Role of leukemia inhibitory factor in nasopharyngeal carcinogenesis.

Authors:  Shu-Chen Liu; Yu-Sun Chang
Journal:  Mol Cell Oncol       Date:  2014-07-15

9.  LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma.

Authors:  Ting-Ting Cai; Shu-Biao Ye; Yi-Na Liu; Jia He; Qiu-Yan Chen; Hai-Qiang Mai; Chuan-Xia Zhang; Jun Cui; Xiao-Shi Zhang; Pierre Busson; Yi-Xin Zeng; Jiang Li
Journal:  PLoS Pathog       Date:  2017-07-21       Impact factor: 6.823

10.  Roles of the kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic viral mimic, LMP1.

Authors:  Kelly M Arcipowski; Gail A Bishop
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.